1 / 8

Pat F. Bass III, MD CMIO LSU-Health Shreveport ICON Steering Committe

Pat F. Bass III, MD CMIO LSU-Health Shreveport ICON Steering Committe. Benefits of LSU ICON for LSUHSC Shreveport. Access to data analysis/statistical support Dedicated Patient Interaction Specialist to assist in recruiting and data collection Centralized research support/ mentoring.

belita
Download Presentation

Pat F. Bass III, MD CMIO LSU-Health Shreveport ICON Steering Committe

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pat F. Bass III, MD CMIO LSU-Health Shreveport ICON Steering Committe

  2. Benefits of LSU ICON for LSUHSC Shreveport • Access to data analysis/statistical support • Dedicated Patient Interaction Specialist to assist in recruiting and data collection • Centralized research support/ mentoring

  3. Current LSU ICON Projects in Shreveport • “Operative and Non-Operative Outcomes in Disorders of the Lumbar Spine” (Donald Smith, MD, Principal Investigator) • “Retrospective Observational Study of Physician Response & Cost Effectiveness of Rapid Identification of Staphylococcus Species & Methicillin Susceptibility Results Using Verigene BC-S Assay in Aerobic Bottles From Adult Hospitalized Bacteremic Patients” (Gerald Capraro, PhD, Principal Investigator)

  4. Collaboration with LSU ICON Resources • Medical Consultants Core • Design & Analysis Core • Network Evaluation Support Team • Biomedical Informatics Core • Health Literacy Core

  5. Operative and Non-Operative Outcomes in Disorders of the Lumbar Spine Summary: This project is designed to compare the operative and non-operative outcomes of some of the most common spinal problems. Such diagnoses as Back Pain, Lumbar Disk Disease and Spinal Stenosis are prevalent in this country and are some of the most frequent sources of disability and pain complaints. Treatment of these problems consume an increasingly large fraction of the present healthcare costs. Various surgical procedures are utilized in the management of such conditions but the relative value of these procedures have not, in most instances, been established. This project attempts to prospectively compare the outcomes of patients, as measured from their perspective and their functional capability, when treated by surgical versus non surgical management.

  6. Operative and Non-Operative Outcomes in Disorders of the Lumbar Spine • Principal Investigator: Donald R. Smith, M.D. • Timeline for Completion: approximately 2 years

  7. Retrospective Observational Study of Physician Response and Cost Effectiveness of Rapid Identification of Staphyloccus Species and Methicillin Susceptibility Results Using Verigene BC-S Assay in Aerobic Bottles from Adult Hospitalized Bacteremic Patients Summary: This projects will determine the effect of a rapid test for identification of bloodstream pathogens on physician response and healthcare costs. Using classical biochemical methods, bacteria are identified within 48 hours; however, we have verified a new test that uses a molecular signal-amplification method to identify methicillin-resistant Staphylococcus aureus (MRSA), methicillin-susceptible Staph. aureus (MSSA), and coagulase-negative staphylococci (CoNS) in 4 hours. MSSA identification allows for a switch from empiric vancomycin therapy to nafcillin, a more effective drug for MSSA, which may cause the patient to get better faster and decrease the length of hospital stay. We will assess clinician response to faster results and determine if there is an impact on healthcare costs. Comparing control patients (with bacteria identified classically) to experimental patients (with bacteria identified molecularly), calculation of healthcare costs may reveal a difference. We expect that faster MSSA results lead to modification of empiric therapy, shorter stay, and decreased costs.

  8. Retrospective Observational Study of Physician Response and Cost Effectiveness of Rapid Identification of Staphyloccus (cont.) • Principal Investigator: Gerald A. Capraro, Ph.DCo-Investigator(s):TaherKatouzian, M.D., Andrew J. Chandranesan, MadhuChhandaChoudhary, M.D. • Timeline for Completion: approximately 1 year (project start pending)

More Related